Costas G. Hadjipanayis, M.D., Ph.D. Principal Investigator of Multicenter Study of 5-ALA

Costas G. Hadjipanayis, M.D., Ph.D.
Principal Investigator of Multicenter Study of 5-ALA

Professor Walter Stummer, M.D., Ph.D. Chairman of Neurosurgery, Munster University Hospital

Professor Walter Stummer, M.D., Ph.D.
Chairman of Neurosurgery, Munster University Hospital

Dr. Georg Widhalm Assistant Professor, Department of Neurosurgery Medical University - Vienna, Austria

Dr. Georg Widhalm
Assistant Professor, Department of Neurosurgery
Medical University - Vienna, Austria


 
8030258_orig.png

Costas G. Hadjipanayis, M.D., PhD
Principal Investigator of Multicenter Study of 5-ALA

Dr. Hadjipanayis received his medical degree from Jefferson Medical College; completed his residency in neurosurgery at the University of Pittsburgh School of Medicine, simultaneously obtaining his PhD from the Department of Molecular Genetics and Biochemistry.

Designated as a Georgia Cancer Coalition Distinguished Scholar, he was elected 2011 President of the Southeastern Brain Tumor Foundation.

Dr. Hadjipanayis is Professor and Chair, Dept. of Neurosurgery, Mount Sinai Beth Israel; and Director, Neurosurgical Oncology, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai.


 
2116736_orig.png

Professor Walter Stummer, M.D., Ph.D.
Chairman of Neurosurgery, Munster University Hospital

Dr. Stummer is a world leader in the introduction and implementation of advanced fluorescence-based diagnostic methods in operation microscopy and microneurosurgery.

He is the neurosurgeon who introduced the use of 5-ALA in the resection of high-grade gliomas, and has published extensively on the 5-ALA method, from applied laboratory research to the operation room. 


 
5844877_orig.png

Dr. Georg Widhalm
Assistant Professor, Department of Neurosurgery
Medical University - Vienna, Austria

Dr. Widhalm is a clinical scientist/surgeon who is a leader in fluorescent-guided surgery focusing upon biomarkers and disease detection. His dissertation work was pivotal in demonstrating the use of Gleolan® for low grade Gliomas that are hiding anaplastic malignancies in 48% of the “nonmalignant" patients. This game changing observation affords the use of Gleolan® in all patients in his hospital to assure maximal tumor removal as standard of care. His insight and expertise underlies his translational approach to novel tumor applications.